Cystatin C is a protease inhibitor proposed as a replacement for serum creatinine for the assessment of renal function, particularly to detect small reductions in glomerular filtration rate. Patients with kidney disease are far more likely to die from cardio vascular disease (CVD), than to develop kidney failure. In this study, we propose a novel model to predict serum cystatin C level to access cardiovascular risks in patients with chronic kidney disease (CKD) through other parameters of CKD.  Blood samples from patients with CKD, CVD and both CKD with CVD, along with the normal healthy controls were collected. Lipid profile, urea, creatinine, hs-CRP, physiological parameters and cystatin C were analysed.  Diabetics proportion were significantly higher among diseased persons as compared to control subjects (p=0.0001). Mean values of total cholesterol, triglyceride, VLDL, urea, creatinine and cystatin C among CKD group as well as in CVD group of patients were significantly higher (p<0.05) as compared to healthy controls. In CKD patients with CVD, the mean values of potassium, glucose, urea, creatinine, cystatin C and total leucocyte count were also significantly higher (p<0.05) as compared to healthy controls. A new formula was generated for calculating serum cystatin C level by extrapolating other parameters of CKD for risk assessment of CVD. The study demonstrated a novel predictive model for assessment of serum cystatin C level which is an endogenous risk marker in the patients of CVD with CKD.